Larimar Therapeutics, Inc. (NASDAQ:LRMR) Holdings Decreased by Two Sigma Advisers LP

Two Sigma Advisers LP reduced its stake in shares of Larimar Therapeutics, Inc. (NASDAQ:LRMR) by 31.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 67,024 shares of the company’s stock after selling 30,100 shares during the quarter. Two Sigma Advisers LP owned about 0.11% of Larimar Therapeutics worth $259,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Janus Henderson Group PLC grew its stake in Larimar Therapeutics by 15.7% during the 4th quarter. Janus Henderson Group PLC now owns 6,443,286 shares of the company’s stock worth $24,936,000 after buying an additional 876,431 shares during the last quarter. Blue Owl Capital Holdings LP grew its stake in Larimar Therapeutics by 11.7% during the 4th quarter. Blue Owl Capital Holdings LP now owns 4,653,040 shares of the company’s stock worth $18,007,000 after buying an additional 486,211 shares during the last quarter. Adage Capital Partners GP L.L.C. grew its stake in Larimar Therapeutics by 23.5% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 2,100,000 shares of the company’s stock worth $8,127,000 after buying an additional 399,123 shares during the last quarter. Alyeska Investment Group L.P. grew its stake in Larimar Therapeutics by 38.6% during the 4th quarter. Alyeska Investment Group L.P. now owns 984,077 shares of the company’s stock worth $3,808,000 after buying an additional 273,920 shares during the last quarter. Finally, Renaissance Technologies LLC grew its stake in Larimar Therapeutics by 45.1% during the 4th quarter. Renaissance Technologies LLC now owns 513,542 shares of the company’s stock worth $1,987,000 after buying an additional 159,700 shares during the last quarter. 91.92% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on LRMR shares. Robert W. Baird lowered their price objective on Larimar Therapeutics from $13.00 to $10.00 and set an “outperform” rating for the company in a research note on Tuesday, March 25th. Guggenheim reiterated a “buy” rating and set a $26.00 price target on shares of Larimar Therapeutics in a research report on Tuesday, March 25th. HC Wainwright boosted their price target on Larimar Therapeutics from $15.00 to $16.00 and gave the stock a “buy” rating in a research report on Tuesday, March 25th. Finally, Citigroup reiterated a “buy” rating on shares of Larimar Therapeutics in a research report on Tuesday, March 25th. Eight analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $19.67.

Larimar Therapeutics Stock Up 8.9%

Shares of Larimar Therapeutics stock opened at $2.68 on Friday. The firm has a market cap of $171.60 million, a price-to-earnings ratio of -2.33 and a beta of 0.79. The business has a fifty day simple moving average of $2.12 and a 200-day simple moving average of $3.27. Larimar Therapeutics, Inc. has a fifty-two week low of $1.61 and a fifty-two week high of $11.20.

Larimar Therapeutics (NASDAQ:LRMR) last announced its quarterly earnings data on Wednesday, April 30th. The company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.42) by ($0.04). Analysts anticipate that Larimar Therapeutics, Inc. will post -1.15 earnings per share for the current fiscal year.

Larimar Therapeutics Profile

Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease.